Answers are grounded in this paper and cite their sources.
This review explores CRISPR-mediated strategies to induce cancer cell death, suggesting promising applications in oncology.
CRISPR-Cas9 is a strong gene editing tool having two components, Cas9 protein and guide RNA. It involves a protospacer adjacent motif (PAM) which is identified by Cas9 endonucleases to initiate double stranded break in DNA, which is repaired by either of two pathways; non-homologous end joining pathway (NHEJ) or homology-directed repair (HDR) pathway .CRISPR/Cas9 can be used to edit the genes involved in apoptosis regulation, to target oncogenes, anti-apoptotic proteins, immune checkpoints, to selectively induce cancer cell death. This review identifies CRISPR-mediated apoptotic approaches, its mechanism, preclinical trials, and issues and points to its possible application in cancer.
No takes yet. Share an insight, caveat, or question.
Hadri et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: